Navigation Links
HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
Date:7/11/2012

CHARLOTTESVILLE, Va., July 11, 2012 /PRNewswire/ -- HemoShear LLC, a biotechnology research company and leading developer of human surrogate systems for discovery and assessment of new drug compounds, today announced a partnership with the genomic services company Expression Analysis (EA) to develop the first comprehensive database for evaluating the vascular pharmacology of new drug compounds. Using HemoShear's human relevant systems, the database will profile how human vascular cells respond at the genomic level to approximately 75 existing drug compounds that span a wide range of drug classes and have been accepted, black-boxed, or withdrawn from the market.

(Logo: http://photos.prnewswire.com/prnh/20120416/PH86899LOGO )

"Pharmaceutical companies can use this database to establish a true risk profile of their compounds and investigate potential positive or negative effects. A number of diabetes drugs, for example, have been shown to have adverse cardiovascular effects in humans. We can provide insights about the risks associated with continuing development of new compound candidates by comparing to other drugs in our database that are related by class, genomic signature or mechanism of action," said Nicole Hastings, Ph.D., HemoShear's Vice President of Laboratory Operations. "We partnered with EA because its staff's unrivaled gene expression expertise and throughput are essential to HemoShear's successful and timely development of this landmark database."

EA will generate the database's extensive genomic content by sequencing more than 2,000 human RNA samples. The product will be the transcriptome of each sample, which correlates to the state of the vascular cells in response to a specific drug.

"Sequencing the transcriptome can reveal the expressed quantities of protein-coding messages and isoforms of all active genes as well as detect novel post-transcriptional modifications that HemoShear and the scientific community have yet to identify as significant. In contrast, traditional techniques such as microarrays can only detect changes in expression of predetermined genetic content within a more limited dynamic range. Transcriptome sequencing enables HemoShear to develop the most comprehensive and sustainable database for evaluating drug vascular safety and efficacy," said Wendell Jones, Ph.D., Vice President of Statistics and Bioinformatics at EA.

The partnership will also extend to support HemoShear's Division of Quantitative and Computational Sciences.  EA will provide the bioinformatics and computational infrastructure necessary to process the large volume of genomic data in a defined format from the study's several thousand human samples with consistency and speed in order to accelerate the development of the database.

This work is funded by a $4.3 million Phase II Small Business Innovation Research grant from the National Heart, Lung and Blood Institute of the National Institutes of Health.

About EA
EA provides cutting-edge genomic sequencing, gene expression, genotyping, and bioinformatics services to the world's largest pharmaceutical companies, diagnostic test developers, government agencies, and academic labs. All projects are conducted under clinical-grade quality control, ensured through CLIA certification, GLP compliance, and adherence to CLSI guidelines. EA's bioinformatics staff are key contributors to the Food and Drug Administration's MicroArray Quality Control (MAQC) and Sequencing Quality Control (SEQC) studies, which aim to improve standards and quality measures for reliable use of next-generation sequencing and gene expression technologies in clinical practice and regulatory decision-making. As part of its mission to improve human health, EA has donated more than $2.2 million towards academic genomic research grants and its "Leave Your Fingerprint on the Cure" Program for pediatric cancer hosted at the American Society for Human Genetics annual meeting.

About HemoShear LLC
HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases throughout drug discovery and development. Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies. HemoShear's science leads to new medicines and improves human health.  


'/>"/>
SOURCE HemoShear LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. HemoShear to Present at Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Conference
2. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
3. Dicom Systems and USARAD.com Announce Partnership and Introduce Beta Version of XMRI.com, New System by USARAD.com
4. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
5. Van Andel Institute Partners with UNCF to Recruit Students to Biomedical Research Careers
6. BioStorage Technologies Partners with Susan G. Komen for the Cure Tissue Bank at IU Simon Cancer Center to Raise Money and Awareness for Breast Cancer Research
7. Cowen Healthcare Royalty Partners Raises $1 Billion
8. Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China
9. CoreLab Partners Opens Office in Tokyo, Japan
10. Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award
11. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... ... software solutions for pharmaceutical research and development (R&D), today announced the launch ... data analysis and interpretation for the rapidly evolving field of precision medicine. ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... Health (NIH) to update its Data Sharing Policy. Specifically, the nation’s leading informatics ... applications subject to the existing policy. AMIA recommended that NIH earmark funding for ...
(Date:1/19/2017)... 18, 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW ... therapies for operable and inoperable solid tumor cancers, announced ... Officer of NW Bio, will present at the Phacilitate ... the Hyatt Regency Hotel in Miami, Florida ... session entitled "New Therapeutic Approaches – Expanding the Reach ...
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical , ... designed to target cancer stemness pathways, will feature data ... napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, held ... . Napabucasin is an orally-administered investigational ... STAT3. i Cancer stem cells (CSCs) possess the ...
Breaking Biology Technology:
(Date:1/12/2017)... and PUNE, India , January 12, 2017 ... Forecasts, 2015 - 2022," projects that the global biometric technology market is expected to ... 2016 to 2022. Continue Reading ... ...      ...
(Date:1/6/2017)... , Jan. 5, 2017  Delta ID Inc., ... iris scanning technology for automotive at CES® 2017. Delta ... GNTX ) to demonstrate the use of iris scanning ... and authenticate the driver in a car, and as ... the driving experience. Delta ID and Gentex ...
(Date:12/22/2016)... 22, 2016 SuperCom (NASDAQ:   ... for the e-Government, Public Safety, HealthCare, and Finance sectors announced today ... been selected to implement and deploy a community-based supportive services program ... California , further expanding its presence in the state. ... This new program, which ...
Breaking Biology News(10 mins):